Related references
Note: Only part of the references are listed.A Phase 1 Safety Study of an IRX-2 Regimen in Patients With Squamous Cell Carcinoma of the Head and Neck
Scott M. Freeman et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2011)
The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time
Junliang Ma et al.
BMC CANCER (2010)
Gene Signature in Melanoma Associated With Clinical Activity A Potential Clue to Unlock Cancer Immunotherapy
Thomas F. Gajewski et al.
CANCER JOURNAL (2010)
Mononuclear phagocytes in head and neck squamous cell carcinoma
Kenneth Wilfried Kross et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2010)
IRX-2 increases the T cell-specific immune response to protein/peptide vaccines
Paul H. Naylor et al.
VACCINE (2010)
IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death
M. Czystowska et al.
CELL DEATH AND DIFFERENTIATION (2009)
Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival
C. M. Ohri et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation
Alberto Mantovani et al.
HUMAN IMMUNOLOGY (2009)
Immunotherapy in head and neck cancer: current practice and future possibilities
F. O. Agada et al.
JOURNAL OF LARYNGOLOGY AND OTOLOGY (2009)
Zinc in Cancer Prevention
Ananda S. Prasad et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2009)
Anti-tumor Vaccines in head and neck cancer: Targeting immune responses to the tumor
Theresa L. Whiteside
CURRENT CANCER DRUG TARGETS (2007)
IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro
James E. Egan et al.
JOURNAL OF IMMUNOTHERAPY (2007)
High macrophage infiltration along the tumor front correlates with improved survival in colon cancer
Johan Forssell et al.
CLINICAL CANCER RESEARCH (2007)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker
Takeshi Ogino et al.
CANCER RESEARCH (2006)
Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer
Robert L. Ferris et al.
CLINICAL CANCER RESEARCH (2006)
Protective mechanisms of head and neck squamous cell carcinomas from immune assault
MRI Young
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2006)
Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers
C Badoual et al.
CLINICAL CANCER RESEARCH (2006)
Immunobiology of head and neck cancer
TL Whiteside
CANCER AND METASTASIS REVIEWS (2005)
Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck
TK Hoffmann et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Lymph node histology in head and neck cancer: impact of immunotherapy with IRX-2
A Meneses et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2003)
Share Paper
